World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF THYROID CANCER USING SIMILAR MOLECULE - 2, 4-DICHLOROPYRIMIDINE

Nazneen*, Dr. Syed Ahmed Hussain, Faheem Unnisa, Arshiya Tarannum, Umaima Batool Osmani, Raheem Unnisa Shaik and Maimuna Fatima

ABSTRACT

Aim: The study aims to evaluate the cytotoxic activity of 2,4-Dichloropyrimidine on kidney cancer cell lines using
various assays to determine its effectiveness compared to the standard drug Lenvatinib. Objective: To assess the
cytotoxicity and viability of kidney cancer cells treated with different concentrations of 2,4-Dichloropyrimidine
using MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH assays. Research: Various cell viability and cytotoxicity
assays were performed, including MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH, on kidney cancer cell lines
treated with 2,4-Dichloropyrimidine. The results demonstrated a concentration-dependent decrease in cell viability,
with higher concentrations of the drug leading to increased cytotoxic effects. This was evident across all assays
used in the study, confirming the drug's potential efficacy against kidney cancer cells. Conclusion: The findings
indicate that 2,4-Dichloropyrimidine exhibits significant cytotoxic activity in kidney cancer cell lines, making it a
potential candidate for further evaluation in cancer therapeutics. When compared with Lenvatinib, 2,4-
Dichloropyrimidine demonstrated comparable activity, highlighting its potential use as an alternative treatment
option for thyroid cancer patients resistant to conventional therapies.

[Full Text Article]   [Download Certificate]